EGFR and neoplasm: Circulating PRL levels in EGFR and HER2 transgenic mice were increased, and inhibiting EGFR or HER2 signaling with oral lapatinib suppressed circulating PRL by 72% and attenuated tumor PRL expression by 80%, and also attenuated downstream tumor EGFR/HER2 signaling [158].